{
    "topic": "business",
    "source": "MarketWatch",
    "bias": 2,
    "url": "https://www.marketwatch.com/story/investors-shift-attention-to-next-generation-of-car-t-new-sickle-cell-treatments-at-major-hematology-meeting-2019-12-10?mod=newsviewer_click",
    "title": "Investors shift attention to next generation of CAR-T, new sickle cell treatments at major hematology meeting",
    "date": "2019-12-10",
    "authors": "Jaimy Lee",
    "content": "A handful of sickle cell disease treatments and CAR-T therapies that treat cancer have been approved by the Food and Drug Administration in recent years , but a new crop of experimental therapies that would grow those markets is exciting investors .\nSee also : Drug manufacturers have spent a record $ 342 billion on M & A in 2019\nThis week , much of the high-profile clinical data coming out of the American Society of Hematology \u2019 s annual meeting in Orlando , Fla. , focused on companies developing products that aim to fit the needs of these patients .\nThe FDA approval in November of two new treatments for sickle cell disease has reinvigorated interest in a long-neglected therapeutic area .\n\u201c The space , which has lacked therapeutics successes for so long , is finally getting its due , \u201d wrote Maxim Group \u2019 s Jason McCarthy on Monday .\nNovartis \u2019 s NVS , +0.23 % Adakveo reduces the frequency of one of the disease \u2019 s complications , while Oxbryta , developed by Global Blood Therapeutics GBT , +1.62 % , treats the root cause of sickle cell anemia . The wholesale list prices for both drugs are about $ 10,000 a month .\nSee also : Fate Therapeutics \u2019 stock rises on early stage cancer drug data\nThat said , analysts paid close attention to data for Bluebird Bio \u2019 s BLUE , +1.78 % investigational gene therapy for sickle cell disease . \u201c As investors digest data presented throughout ASH ( especially in [ sickle cell disease ) , we expect BLUE to outperform peers substantially , \u201d wrote SVP Leerink analysts .\nThe Cambridge , Mass.-based biotech plans to initiate a Phase 3 trial next year after releasing positive data for LentiGlobin in a Phase 1/2 study . The therapy showed a reduction in vaso-occlusive crises and acute chest syndrome ( both complications of sickle cell disease ) in some patients . Shares of Bluebird , which also presented data on its experimental CAR-T therapy and LentiGlobin as a treatment for severe beta-thalassemia , at ASH , were up 10 % in afternoon trading on Tuesday .\nIn 2017 , the FDA approved the first CAR-T therapy\u2014Novartis \u2019 s Kymriah\u2014as a treatment for certain patients with acute lymphoblastic leukemia . Gilead Sciences \u2019 GILD , -0.16 % Yescarta soon followed , as a treatment for certain types of large B-cell lymphoma . ( Unlike oral or infused drugs , chimeric antigen receptor T cell , or CAR-T , therapy involves removing a patient \u2019 s immune cells , shipping them to a manufacturing facility to be re-engineering , and then sending them back to be placed back in the patient \u2019 s body . )\nNow that field is getting crowded , with both large and small pharmaceutical companies . This week , Bluebird and Bristol-Myers Squibb BMY , +0.21 % shared results from their early-stage trial for an experimental CAR-T therapy treating multiple myeloma . BMS also said Saturday that a pivotal trial for liso-cel , its investigational CAR-T treatment , showed high rates of durable responses , and it will submit an application to the FDA this month . Johnson & Johnson JNJ , +0.33 % is developing a CAR-T for multiple myeloma . The pharma company presented mid-stage study data that Bernstein analysts called \u201c clearly impressive and will need to be watched . \u201d\nRead : Precision BioSciences stock rises on early stage CAR-T trial data\nThat said , some of the experimental therapies are hoping to capitalize on the costs associated with CAR-T treatment . The currently available CAR-T therapies are expensive . At launch , Kymriah cost $ 475,000 , and Yescata $ 373,000 .\n\u201c Hospitals have been struggling with the cost of CAR-T as the patients require hospitalization within [ three days ] of treatment , which means the treatment is considered inpatient and reimbursed \u201d as part of transplantation diagnostic related grouping , \u201d Berstein \u2019 s Ronny Gal wrote this week .\nAbout one-quarter of the patients in the liso-cel trial were treated in an outpatient setting , which is less expensive than if a patient is hospitalized . If approved , that change in setting may shift the market away from an already approved therapy , such as Yescarta , to one that can deliver on a more cost-effective approach .\nThe headlining deal in hematology right now is Merck \u2019 s MRK , +1.79 % $ 2.7 billion buyout of ArQule ARQL , +0.15 % , a biopharmaceutical company developing treatments for cancer and rare diseases . The deal , announced Monday , will add ArQule \u2019 s mid-stage therapeutic candidate , ARG 531 , a Bruton \u2019 s tyrosine kinase ( BTK ) inhibitor , to Merck \u2019 s high-performing oncology portfolio . Shares of ArQule were up 1.27 % in afternoon trading on Tuesday .\n\u201c We see this acquisition as unlocking value for investors as it places ARQ 531 in the hands of a larger player who can develop this asset more broadly and aggressively , \u201d Jonathan Chang , an analyst at SVB Leerink , wrote in a note .",
    "content_original": "A handful of sickle cell disease treatments and CAR-T therapies that treat cancer have been approved by the Food and Drug Administration in recent years, but a new crop of experimental therapies that would grow those markets is exciting investors.\n\nSee also: Drug manufacturers have spent a record $342 billion on M&A in 2019\n\nThis week, much of the high-profile clinical data coming out of the American Society of Hematology\u2019s annual meeting in Orlando, Fla., focused on companies developing products that aim to fit the needs of these patients.\n\nNew interest in sickle cell disease\n\nThe FDA approval in November of two new treatments for sickle cell disease has reinvigorated interest in a long-neglected therapeutic area.\n\n\u201cThe space, which has lacked therapeutics successes for so long, is finally getting its due,\u201d wrote Maxim Group\u2019s Jason McCarthy on Monday.\n\nNovartis\u2019s NVS, +0.23% Adakveo reduces the frequency of one of the disease\u2019s complications, while Oxbryta, developed by Global Blood Therapeutics GBT, +1.62%, treats the root cause of sickle cell anemia. The wholesale list prices for both drugs are about $10,000 a month.\n\nSee also: Fate Therapeutics\u2019 stock rises on early stage cancer drug data\n\nThat said, analysts paid close attention to data for Bluebird Bio\u2019s BLUE, +1.78% investigational gene therapy for sickle cell disease. \u201cAs investors digest data presented throughout ASH (especially in [sickle cell disease), we expect BLUE to outperform peers substantially,\u201d wrote SVP Leerink analysts.\n\nThe Cambridge, Mass.-based biotech plans to initiate a Phase 3 trial next year after releasing positive data for LentiGlobin in a Phase 1/2 study. The therapy showed a reduction in vaso-occlusive crises and acute chest syndrome (both complications of sickle cell disease) in some patients. Shares of Bluebird, which also presented data on its experimental CAR-T therapy and LentiGlobin as a treatment for severe beta-thalassemia, at ASH, were up 10% in afternoon trading on Tuesday.\n\nThe CAR-T field prepares for competition\n\nIn 2017, the FDA approved the first CAR-T therapy\u2014Novartis\u2019s Kymriah\u2014as a treatment for certain patients with acute lymphoblastic leukemia. Gilead Sciences\u2019 GILD, -0.16% Yescarta soon followed, as a treatment for certain types of large B-cell lymphoma. (Unlike oral or infused drugs, chimeric antigen receptor T cell, or CAR-T, therapy involves removing a patient\u2019s immune cells, shipping them to a manufacturing facility to be re-engineering, and then sending them back to be placed back in the patient\u2019s body.)\n\nNow that field is getting crowded, with both large and small pharmaceutical companies. This week, Bluebird and Bristol-Myers Squibb BMY, +0.21% shared results from their early-stage trial for an experimental CAR-T therapy treating multiple myeloma. BMS also said Saturday that a pivotal trial for liso-cel, its investigational CAR-T treatment, showed high rates of durable responses, and it will submit an application to the FDA this month. Johnson & Johnson JNJ, +0.33% is developing a CAR-T for multiple myeloma. The pharma company presented mid-stage study data that Bernstein analysts called \u201cclearly impressive and will need to be watched.\u201d\n\nRead: Precision BioSciences stock rises on early stage CAR-T trial data\n\nThat said, some of the experimental therapies are hoping to capitalize on the costs associated with CAR-T treatment. The currently available CAR-T therapies are expensive. At launch, Kymriah cost $475,000, and Yescata $373,000.\n\n\u201cHospitals have been struggling with the cost of CAR-T as the patients require hospitalization within [three days] of treatment, which means the treatment is considered inpatient and reimbursed\u201d as part of transplantation diagnostic related grouping,\u201d Berstein\u2019s Ronny Gal wrote this week.\n\nAbout one-quarter of the patients in the liso-cel trial were treated in an outpatient setting, which is less expensive than if a patient is hospitalized. If approved, that change in setting may shift the market away from an already approved therapy, such as Yescarta, to one that can deliver on a more cost-effective approach.\n\nM&A takes center stage\n\nThe headlining deal in hematology right now is Merck\u2019s MRK, +1.79% $2.7 billion buyout of ArQule ARQL, +0.15%, a biopharmaceutical company developing treatments for cancer and rare diseases. The deal, announced Monday, will add ArQule\u2019s mid-stage therapeutic candidate, ARG 531, a Bruton\u2019s tyrosine kinase (BTK) inhibitor, to Merck\u2019s high-performing oncology portfolio. Shares of ArQule were up 1.27% in afternoon trading on Tuesday.\n\n\u201cWe see this acquisition as unlocking value for investors as it places ARQ 531 in the hands of a larger player who can develop this asset more broadly and aggressively,\u201d Jonathan Chang, an analyst at SVB Leerink, wrote in a note.",
    "source_url": "www.marketwatch.com",
    "bias_text": "right",
    "ID": "LCTebaYxKXU53OTA"
}